Drugs / THR-687
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03666923 | Sep 2018 → Nov 2019 | diabetes mellitus, diabetic macular edema | ThromboGenics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05063734 | Aug 2021 → Jun 2022 | diabetes mellitus, diabetic macular edema | Oxurion | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2022-05-09 | ThromboGenics | Results Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME) oxurion.com ↗
Trial did not demonstrate efficacy on the key clinical endpoints |
| 2022-05-03 | ThromboGenics | Results Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting oxurion.com ↗
Preclinical data shows THR-687s potent inhibition of vascular permeability, inflammation and reactive gliosis in diabetic rats supporting evidence of clinical utility of THR -687 in multiple retinal diseases. |
| 2021-08-17 | ThromboGenics | Results Oxurion NV – Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal oxurion.com ↗
For this highest dose, a mean BCVA Improvement of 11 letters was noted at Day 1 4, with a peak improvement of 12.5 letters at Month 3. |
| 2021-08-16 | ThromboGenics | Results Oxurion NV – Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of THR-687 and THR-149 oxurion.com ↗
THR-149 and THR-687 show targeted activity in the eye following intravitreal injection with low systemic exposure |
| 2020-09-29 | ThromboGenics | Results Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4 oxurion.com ↗
This study showed that THR-687, a pan-RGD integrin antagonist, potently inhibits retinal vascular permeability, inflammation, pericyte loss and gliosis induced by diabetes in the STZ rat. |
| 2020-02-09 | ThromboGenics | Results Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME, at Angiogenesis, Exudation, and Degeneration 2020 Conference oxurion.com ↗
The topline Phase 1 data showed that THR-687 was safe and well tolerated at all of the dose levels tested. |
| 2020-01-07 | ThromboGenics | Results Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME oxurion.com ↗
today reports positive topline data from a Phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of Diabetic Macular Edema (DME). |
All press releases naming this drug 17 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THR-687 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03666923 ↗ |
| Route | Intravitreal | “single intravitreal injection of THR-687 dose level 1” NCT03666923 ↗ |